ULGX
Urologix, Inc.

MINNEAPOLIS, May 5, 2015 (GLOBE NEWSWIRE) -- Urologix, Inc. (OTCQB:ULGX) will host a conference call to present third quarter fiscal year 2015 results on Tuesday, May 12, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-877-359-9508 and enter the conference ID 42703418 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.

Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until May 19, 2015 at 10:59 p.m. CT. To listen to the replay, please dial 1-855-859-2056 and enter the conference ID 42703418.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix's Cooled ThermoTherapy™ system produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis catheter families. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

CONTACT: Scott Madson
         Chief Financial Officer
         Urologix, Inc.
         763-475-1400
         investor-relations@urologix.com